KROS - Keros Therapeutics Inc
11.27
-0.310 -2.751%
Share volume: 625,841
Last Updated: 03-11-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.16%
PREVIOUS CLOSE
CHG
CHG%
$11.58
-0.31
-0.03%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-08-2024 | 08-07-2024 | 11-06-2024 | 02-26-2025 | 05-06-2025 | 11-05-2025 | 03-04-2026 | |
| Assets | ||||||||
| Total Assets | 485.819 M | 455.022 M | 579.271 M | 615.886 M | 784.561 M | 742.783 M | 338.021 M | |
| Current Assets | 463.126 M | 432.714 M | 552.046 M | 588.893 M | 759.509 M | 719.307 M | 315.434 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 442.443 M | 405.863 M | 530.684 M | 559.931 M | 720.541 M | 693.472 M | 287.415 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 4.434 M | 4.292 M | 4.366 M | 4.237 M | 4.473 M | 4.564 M | 4.297 M | |
| Other Assets | 18.259 M | 18.016 M | 22.859 M | 22.756 M | 20.579 M | 18.912 M | 18.290 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 485.819 M | 455.022 M | 579.271 M | 615.886 M | 784.561 M | 742.783 M | 338.021 M | |
| Total liabilities | 31.872 M | 34.106 M | 46.436 M | 44.333 M | 55.690 M | 39.203 M | 34.889 M | |
| Total current liabilities | 18.718 M | 21.245 M | 29.007 M | 27.450 M | 39.379 M | 24.092 M | 20.414 M | |
| Accounts Payable | 4.986 M | 6.535 M | 4.981 M | 4.602 M | 6.636 M | 2.298 M | 1.967 M | |
| Other liabilities | 13.154 M | 12.861 M | 17.429 M | 16.883 M | 16.311 M | 15.111 M | 14.475 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 13.154 M | 12.861 M | 17.429 M | 16.883 M | 16.311 M | 15.111 M | 14.475 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 453.947 M | 420.916 M | 532.835 M | 571.553 M | 728.871 M | 703.580 M | 303.132 M | |
| Common stock | 878.487 M | 890.713 M | 1.056 B | 1.140 B | 1.149 B | 1.162 B | 1.169 B | |
| Retained earnings | -424.540 M | -469.797 M | -522.753 M | -568.779 M | -420.328 M | -458.304 M | -481.765 M |